## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1634

In re Patent Application of: Examiner: B. L. Sisson

Susan HARDIN et al.
Serial No.: 09/901.782

Filing Date: July 9, 2001

For: COMPOSITIONS FOR REAL-TIME

NUCLEOTIDE SEQUENCE DETERMINATION

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## Dear Madam:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to consider and make these documents of record.

Document numbers 184-189 are from Patent Interference No. 105,677 (SGL), which involves related U.S. Patent No. 7,329,492 and application number 11/459,182.

Applicants list below the related U.S. Patents and applications to the present application:

Application Number	Patent Number	Status
09/901,782		Pending
11/007,642		Pending
11/007,794		Pending
11/007,797	7,329,492	Interference 105,677 (SGL)
		Re-Issue 12/321,343
11/648,106		Pending
11/648,115		Pending
11/648,136		Pending
11/648,137		Pending
11/648,138		Pending
11/648,164		Pending
11/648,174		Pending
11/648,182		Pending
11/648,184		Pending
11/648,191		Pending
11/648,713		Pending
11/648,722		Pending
11/648,856		Pending
12/321,343		Pending

Applicants also call to the attention of the Office a concurrent Opposition proceeding against related European Patent No. 1 368 460. Document number 190 is from this Opposition proceeding. The EP Opposition was based on the following references:

- WO 00/70073
- WO 00/17330
- WO 00/53805
- WO 01/16375
- JU et al., Analytical Biochem. (1995) 231:131-140
- POLLOK and HEIM, Trends in Cell Biology (1999) 9:57-60
- FUREY, Biochemistry (1998) 37:2979-2990

• GLAZER and MATHIES, Current Opinion in Biotechnology (1997) 8:94-102

	This Inf	formation Disclosure Statement is submitted:		
	With the application; accordingly, no fee or separate requirements are required.			
$\boxtimes$	Befor	e the mailing of a first Office Action after the filing of a Request for Continued		
	Exam	ination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97		
	(e)(1)	(e)(1) has been provided.		
	Withi	in three months of the application filing date or before mailing of a first Office Action		
	on the	merits; accordingly, no fee or separate requirements are required. However, if		
	applic	applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.		
	After	After receipt of a first Office Action on the merits but before mailing of a final Office Action		
	or Notice of Allowance.			
		A fee is required. A check in the amount of is enclosed.		
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to		
		this submission in duplicate.		
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is		
		believed to be due.		
	After	fter mailing of a final Office Action or Notice of Allowance, but before payment of the		
	issue fee.			
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the		
		amount of is enclosed.		
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal		
		form (PTO/SB/17 is attached to this submission in duplicate.)		

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under

37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has

been made; (ii) additional information material to the examination of this application does not exist;
(iii) the information, protocols, results and the like reported by third parties are accurate or enabling;

or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the

Patent and Trademark Office determines that an extension and/or other relief (such as payment of a

fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including

extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to <u>Deposit Account No. 03-1952</u>

referencing 548642003100.

Dated: March 10, 2009

Respectfully submitted,

Electronic signature: /Daniel A. Rubé/

Daniel A. Rubé

Registration No.: 53,536

MORRISON & FOERSTER LLP 12531 High Bluff Drive, Suite 100

San Diego, California 92130-2040

(858) 720-7987

Serial No. 09/901,782 Docket No. 548642003100

4